Schizophrenia

CT-155, a smartphone-based prescription digital therapeutic, addresses an unmet need in schizophrenia, showing safety and efficacy in a phase 3 trial.

A study of patients with schizophrenia at a psychiatric hospital in China showed that focused group therapy in combination with antipsychotic medication is linked to improvement in depression and other aspects of mental health.

Large language models (LLMs) were more likely to suggest inferior treatment options when reviewing hypothetical cases when patients' Black identity was listed or implied.

One paper compares aripiprazole, cariprazine and brexpiprazole for first-episode use. Another measures long-term outcomes for an aripiprazole monthly injectable.

Although a warming planet is bad for human health overall, the prognosis for schizophrenia is particularly poor, researchers argue in a commentary.

The authors of an opinion piece in The Lancet Psychiatry make a case for paying more attention to the autistic features of schizophrenia.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Meanwhile, newly approved Cobenfy and the long-acting injectable antipsychotics may help with the long-standing problem of nonadherence to schizophrenia treatment.

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.